Company intelligence / Profile preview
Adynxx, Inc.
San Francisco, California, USApmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Phase 1
01
Overview
Adynxx’s lead candidate brivoligide (formerly AYX1) reached Phase 2 clinical trials for the reduction of postoperative pain. Clinical studies suggest a single administration at surgery can reduce pain and opioid use in high-risk patients. Other programs are in preclinical or pending stages targeting chronic and neuropathic pain as well as endometriosis. Some pipeline programs have been discontinued or are pending further development.
- Therapeutic areas
- Women's HealthNeurology
- Modalities
- Transcription factor decoy oligonucleotides (short synthetic double-stranded DNA molecules)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Collaboration with twoXAR to discover/develop treatments for endometriosis using AI-driven drug discovery technology.
Beyond the preview
Go deeper on Adynxx, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adynxx, Inc..